Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T69985 | Lifirafenib HCl | ||
Lifirafenib, also known as Beigene-283, is a Novel potent and selective RAF Kinase and EGFR inhibitor. BGB-283-displays Potent Antitumor Activity in B-RAF Mutated Colorectal Cancers. In vitro, BGB-283 potently inhibits B-RAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harbouring B-RAFV600E and EGFR mutation/amplification. In B-RAFV600E CRC cell lines, BGB-283 effectively inhibits the ... | |||
T22272 |
Lifirafenib
BGB-283,Beigene-283 |
EGFR; Raf | Angiogenesis; JAK/STAT signaling; MAPK; Tyrosine Kinase/Adaptors |
Lifirafenib (Beigene-283) 是新型高效的Raf 激酶和EGFR 抑制剂,对重组BRafV600E 和EGFR 的IC50值分别为 23 和 29 nM。 |